SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. Isordil Sublingual (Isosorbide Dinitrate) without prescription (NASDAQ:EXEL) today announced the appointment of
Christopher J. About Niaspan (Niacin) with no prescription Senner as Executive Vice President and Chief Financial
Officer. Buy Vigora (Sildenafil Citrate) without Rx Mr. Buy Dexamethasone Senner has nearly 25 years of experience in
biopharmaceutical finance, including deep expertise in global financial
operations and controls, strategic planning and analysis, supply chain
finance and business development. Buy Vigora (Sildenafil Citrate) without Rx He joins Exelixis after five years at
Gilead Sciences, where he served as Vice President, Corporate Finance. Buy Stretch Marks online
He previously spent eighteen years at Wyeth in a variety of financial
roles with increasing responsibility for many of the company’s divisions
and regions. http://allegra-opinion.blogspot.com He joins Exelixis in advance of several potentially
transformational milestones anticipated this year, including top-line
results from the METEOR phase 3 pivotal trial and the potential U.S. and
EU regulatory approvals of cobimetinib, a compound discovered by
Exelixis and then licensed to Genentech for further development and
commercialization.
In this role, Mr. Senner will oversee the company’s global finance
function, leveraging extensive experience gained earlier in his career.
While at Gilead, he was accountable for controllership and operational
financial planning and analysis, including research and development,
manufacturing, commercial operations, and tax and treasury planning. At
Wyeth, he served in a variety of capacities, most notably as CFO of the
company’s $10 billion U.S. pharmaceuticals business and the BioPharma
Business Unit, a $5 billion global inflammation, oncology and hematology
business.
“With more than 25 years of service between two of the biopharmaceutical
industry’s most highly-regarded companies, Chris Senner is exceptionally
well prepared to lead Exelixis’ finance function as our next CFO,” said
Michael M. Morrissey, Ph.D., President and Chief Executive Officer of
Exelixis. “Chris’ global commercial finance expertise will serve
Exelixis well as we prepare for top-line results from METEOR and the
potential regulatory approval of cobimetinib, two milestones that we
hope will advance and accelerate the company’s transformation into a
global commercial organization.”
Mr. Senner will succeed Deborah Burke, who has served as Senior Vice
President and Chief Financial Officer since September 2014. Ms. Burke
joined Exelixis in 2005 and was the company’s Vice President, Finance
and Controller before being appointed interim CFO in June 2014. She will
remain with Exelixis in the role of Senior Vice President, Finance and
Controller.
“I’d like to thank Debbie for her many contributions as Chief Financial
Officer over this past year. Her support has been invaluable as we have
navigated through a challenging time for the company,” continued Dr.
Morrissey. “We are fortunate that we will continue to have the benefit
of her input and experience as we move forward.”
“It is a very exciting time to join Exelixis,” said Mr. Senner. “Should
its near-term catalysts prove positive, the company is poised to make
additional, important contributions to the treatment of cancer and
dramatically advance its commercial presence. I’m looking forward to
working with Mike, Debbie and the rest of the Exelixis team to make the
most of the potential opportunities that lie ahead.”
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of
multiple receptor tyrosine kinases. Another Exelixis-discovered
compound, cobimetinib, a selective inhibitor of MEK, is being evaluated
by Roche and Genentech (a member of the Roche Group) in a broad
development program under a collaboration with Exelixis. For more
information, please visit the company s web site at .exelixis.com.
Forward-Looking Statements
This press release contains forward-looking statements, including,
without limitation, statements related to: anticipated developments and
timing with respect to Exelixis’ ongoing phase 3 pivotal METEOR trial of
cabozantinib in renal cell carcinoma; cobimetinib regulatory filings and
future potential approvals; and, Exelixis’ belief that its compounds
have the potential to meaningfully improve cancer care. Words such as
“potential,” “transformation,” “anticipates,” “will,” “advance,” “hope,”
“looking forward,” “believe,” “poised,” or other similar expressions,
identify forward-looking statements, but the absence of these words does
not necessarily mean that a statement is not forward-looking. In
addition, any statements that refer to expectations, projections or
other characterizations of future events or circumstances are
forward-looking statements. These forward-looking statements are based
upon Exelixis’ current plans, assumptions, beliefs, expectations,
estimates and projections. Forward-looking statements involve risks and
uncertainties. Exelixis’ actual results and the timing of events could
differ materially from those anticipated in the forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation: the availability of data at the expected times;
risks related to the potential failure of cabozantinib, cobimetinib and
other Exelixis compounds to demonstrate safety and efficacy in clinical
testing; the clinical, therapeutic and commercial value of cobimetinib,
cabozantinib and other Exelixis compounds; Exelixis’ dependence on its
relationship with Genentech/Roche with respect to cobimetinib and
Exelixis’ ability to maintain its rights under the collaboration; the
uncertainty of regulatory approval processes; the sufficiency of
Exelixis’ capital and other resources; the uncertain timing and level of
expenses associated with the development of cabozantinib; risks and
uncertainties related to Exelixis’ compliance with applicable regulatory
requirements, including healthcare fraud and abuse laws and
post-marketing requirements; Exelixis’ dependence on third-party
vendors; market competition; changes in economic and business
conditions; and other factors discussed under the caption “Risk Factors”
in Exelixis’ quarterly report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on April 30, 2015 and in Exelixis’ other
filings with the SEC. The forward-looking statements made in this press
release speak only as of the date of this press release. Exelixis
expressly disclaims any duty, obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Exelixis’ expectations with
regard thereto or any change in events, conditions or circumstances on
which any such statements are based.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
No comments:
Post a Comment